Lifecycle Management Trends In China Show The Need To Get Ready For Fewer, Better Generics
This article was originally published in PharmAsia News
In China, multinational pharmaceutical companies are not so worried about the patent cliff, as many off-patent products enjoy premium pricing and high-growth rates even when dozens of generics exist. But how long will the party last?
You may also be interested in...
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.